Omics Data for Disease Prediction: Machine Learning Application Based on TCGA Breast Cancer RNA-seq

This project focuses on the interdisciplinary field of bioinformatics and machine learning, using TCGA (The Cancer Genome Atlas) breast cancer RNA-seq gene expression data to build disease prediction models. It covers the entire workflow of data preprocessing, feature engineering, model training, and evaluation, discusses the technical challenges and medical application value of omics data analysis, and provides references for precision medicine.

Omics Data Revolution in the Precision Medicine Era

With the development of high-throughput sequencing technology, biomedicine has entered the era of omics big data. Multi-level omics data provides new dimensions for understanding disease mechanisms and predicting risks. This project focuses on transcriptomic RNA-seq data to explore the association between gene expression and disease states.

RNA-seq Technical Principles and Data Characteristics

RNA-seq obtains RNA sequence information through high-throughput sequencing and quantifies gene expression. Compared to microarrays, it is more sensitive and has a wider dynamic range. Data characteristics: high-dimensional sparsity (tens of thousands of genes, some active), batch effects (need correction), negative binomial distribution (special statistical processing), high-dimensional small samples (few samples, many features).

TCGA Database and Breast Cancer Dataset

TCGA is an important public resource for cancer research, containing multi-omics data for 33 types of cancer. Breast cancer (BRCA) has the largest sample size, including multi-dimensional data such as gene expression, clinical phenotypes, genomic variations, and methylation, providing rich features for prediction models.

Data Preprocessing

Raw RNA-seq needs standardization:

• TPM/FPKM standardization: eliminate the influence of gene length and sequencing depth
• log2 transformation: compress the range to approximate normal distribution
• Batch effect correction: methods like ComBat to eliminate systematic bias
• Low-expression gene filtering: remove low-expression genes to reduce noise

Feature Engineering

Facing high-dimensional features, screening is needed:

• Variance filtering: retain genes with large variation
• Differential expression analysis: DESeq2, edgeR to screen differentially expressed genes between disease and control groups
• Pathway enrichment analysis: map to pathway level for dimensionality reduction
• Machine learning feature selection: LASSO, random forest importance to screen predictive features

Regularized Linear Models

• LASSO (L1 regularization): feature selection + training, sparse solution suitable for high-dimensional data
• Elastic Net: combines L1/L2 regularization, more stable in handling correlated features

Ensemble Learning Methods

• Random Forest: robust to high dimensions, not easy to overfit, provides feature importance
• Gradient Boosting Trees (XGBoost/LightGBM): strong ability to handle nonlinear relationships, excellent performance in omics tasks

Deep Learning Methods

• Autoencoder: unsupervised feature learning, extract low-dimensional latent representations
• Graph Neural Network: use gene regulation/protein interaction networks to enhance prediction

Cross-Validation

Stratified K-fold cross-validation to ensure consistent class proportions in each fold; time-sensitive splitting for survival prediction.

Independent Validation Set

The final model is evaluated on an independent test set that is invisible throughout the process.

Permutation Test

Shuffle labels and train multiple times to establish a significance baseline and avoid random results.

External Validation

Validate on different datasets to prove cross-dataset generalization ability.

Feature Importance Analysis

Identify genes with large predictive contributions, which may be disease biomarkers or therapeutic targets.

Pathway Enrichment Analysis

Map important genes to KEGG and GO databases to understand biological pathway functions.

SHAP/LIME Interpretation

Local interpretation for individual samples to understand the basis of model judgments.

Network Analysis

Construct gene co-expression/protein interaction networks to identify key regulatory modules and hub genes.

Batch Effects and Data Heterogeneity

Data distributions vary greatly across different studies/platforms, making cross-dataset generalization difficult.

Sample Imbalance

More disease samples than normal controls affect model training and evaluation.

Multiple Testing Problem

Testing tens of thousands of genes requires strict statistical correction to control the false positive rate.

Limitations of Causal Inference

Machine learning finds statistical associations rather than causality; gene changes may be the result of disease.

Clinical Translation Gap

Excellent laboratory models do not mean clinical usability; clinical validation and approval are required.

Future Directions

• Multi-omics integration: combine multi-level data such as genomics and transcriptomics
• Single-cell sequencing: analyze tumor heterogeneity and discover rare cell subpopulations
• Federated learning: cross-institutional collaborative training under privacy protection
• Causal inference: identify causal biomarkers to guide treatment
• Clinical decision support: integrate models into clinical workflows to assist doctors

Summary

The combination of omics and machine learning opens up prospects for precision medicine. The RNA-seq prediction workflow demonstrated in this project is a standard paradigm in bioinformatics. Although facing challenges such as high-dimensional small samples and batch effects, technological progress will promote its clinical application.